Document Detail
The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification
Abstract/OtherAbstract :
Ectopic calcification is a frequent complication of many degenerative diseases. Here we identify the serum protein α2–Heremans-Schmid glycoprotein (Ahsg, also known as fetuin-A) as an important inhibitor of ectopic calcification acting on the systemic level. Ahsg-deficient mice are phenotypically normal, but develop severe calcification of various organs on a mineral and vitamin D–rich diet and on a normal diet when the deficiency is combined with a DBA/2 genetic background. This phenotype is not associated with apparent changes in calcium and phosphate homeostasis, but with a decreased inhibitory activity of the Ahsg-deficient extracellular fluid on mineral formation. The same underlying principle may contribute to many calcifying disorders including calciphylaxis, a syndrome of severe systemic calcification in patients with chronic renal failure. Taken together, our data demonstrate a critical role of Ahsg as an inhibitor of unwanted mineralization and provide a novel therapeutic concept to prevent ectopic calcification accompanying various diseases.
Authors :
Schäfer, Cora, Heiss, Alexander, Schwarz, Anke, Westenfeld, Ralf, Ketteler, Markus, Floege, Jürgen, Müller-Esterl, Werner, Schinke, Thorsten, Jahnen-Dechent, Willi
Contributors :
-
Publication Detail :
Publisher :  American Society for Clinical Investigation     Type :  Text     Format :  -    
Date Detail :
-
Subject :
Article
Coverage :
-
Relation :
-
Source :
-
Copyright Information :
Copyright © 2003, American Society for Clinical Investigation
Other Details :
Languages :  en    
Export Citation :
APA/MLA Format     Download EndNote     Download BibTex

Previous Document:  Adenosine mediates IL-13–induced inflammation and remodeling in the lung and interacts in an IL-13...
Next Document:  Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer diseas...